Contraception, Macro-progestins
Conditions
Keywords
Macro-progestins, Bone health
Brief summary
Many factors are known to influence the acquisition of bone capital, especially estrogens in women. Estrogens have a major role in bone growth and the acquisition of bone mass peaks during puberty. This peak of bone mass is an important determinant of the risk of osteoporotic fracture in adulthood. It is known that estrogen deficiency increases the rate of bone remodeling and engenders an imbalance between resorption and bone formation, which can lead to osteoporosis. Oral estroprogestin contraceptives have an anti-gonadotropic effect and suppress estrogen secretion by the ovaries. However, studies in adolescents and young adults are rare and evidence of an effect on bone is still inconclusive, although there is increasing evidence that oral estroprogestin contraceptives in teenage girls may compromise the performance of the bone mass. Macro progestins treatments are prescribed in France to patients with contraindications to estroprogestin treatments. This practice is french and few recommendations exist on the use of these molecules by the oral route. There are no studies that describe the impact of these oral treatments on the bone health of young women treated. The Department of endocrinology, gynecology and pediatric diabetes of Necker-Enfants Malades hospital, follows many young girls taking a macro progestin treatment. This study is exclusively descriptive and will focus on the clinical and medical datas available on the bone health of these patients.
Interventions
OTHERQuestionnaire
Fardellone questionnaire (evaluation of calcium intake) Tolerance of treatment
Sponsors
Assistance Publique - Hôpitaux de Paris
URC-CIC Paris Descartes Necker Cochin
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
16 Years to 25 Years
Healthy volunteers
No
Inclusion criteria
* Patients aged 16 to 25 years old * Patients followed at Necker-Enfants Malades hospital * Patients who have taken or taking macro-progestins treatment by oral route (Luteran, Lutenyl, Surgestone) for at least 6 months between the age of 16 and 25 years
Exclusion criteria
* Patients with a pathology or treatment that can alter bone mineral density
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Bone densitometry | Day 0 | Z score values compared to the reference values |
| Calcemia | Day 0 | Blood test |
| Ionized calcium | Day 0 | Blood test |
| Phosphor | Day 0 | Blood test |
| Magnesium | Day 0 | Blood test |
| Albumin | Day 0 | Blood test |
| Parathormone | Day 0 | Blood test |
| 25 OH vitamin D3 | Day 0 | Blood test |
| Creatinine | Day 0 | Blood test |
| Osteocalcin | Day 0 | Blood test |
| Bone alkaline phosphatase isoenzymes | Day 0 | Blood test |
| C-terminal telopeptide of type I collagen | Day 0 | Blood test |
| Calciuria | Day 0 | Urine test |
| Natriuresis | Day 0 | Urine test |
| Creatinuria | Day 0 | Urine test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical tolerance of treatment | Day 0 | 6 questions asked to the patient under treatment, a yes or no answer is expected : presence of menstruating, regularity of cycles, out-of-periods bleeding, weight gain, acne, satisfaction in relation to treatment. |
| Follicle stimulating hormone | Day 0 | Blood test, patients under macro progestin treatment at day 0 |
| Gonadotrophin b LH | Day 0 | Blood test, patients under macro progestin treatment at day 0 |
| Estradiol | Day 0 | Blood test, patients under macro progestin treatment at day 0 |
Countries
France
Contacts
STUDY_DIRECTORSabrina Da Costa, MD
Hôpital Necker-Enfants Malades
Outcome results
None listed